Computed Tomography (CT) and Lung Function Data Collection for Computational Fluid Dynamics (CFD) in Chronic Obstructive Pulmonary Disease (COPD) Patients

Computed Tomography (CT) and Lung Function Data Collection for Computational Fluid Dynamics (CFD) in COPD Patients

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00966459

Enrollment

Registered

2009-08-27

Start date

2008-11-30

Completion date

2009-05-31

Last updated

2009-09-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Obstructive Pulmonary Disease

Keywords

COPD

Brief summary

In this study, 20 COPD patients will undergo a high-resolution/multi slice CT scan and lung function tests to obtain patient specific geometries of the central and peripheral small airways and patient specific boundary conditions. With Computational Fluid Dynamics (CFD), the investigators will be able to reconstruct the geometry and measure the resistance of the peripheral airways. In a later stage, CFD will be used to simulate the reaction of the airways on various inhalation medications.

Interventions

PROCEDUREComputed Tomography

1 low-dose CT is taken

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

DIAGNOSTIC

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

40 Years to No maximum

Healthy volunteers

Inclusion criteria

1. Patients with documented COPD based on the following criteria: * Smoking history of at least 10 pack-years. * Decreased Tiffeneau index (FEV1/(F)VC \< 0.70). 2. Patients aged ≥ 40 years. 3. Patients should present moderate to very severe COPD with an FEV1 \< 80% of predicted (GOLD 2, 3 and 4). 4. Patients should be treated according to GOLD guidelines. 5. Maintained on stable respiratory medications for 4 weeks prior to visit 1 6. Able to perform lung function tests.

Exclusion criteria

1. Patients below the age of 40. 2. Patients who are pregnant or are breast-feeding. 3. A respiratory infection or exacerbation of COPD in the four weeks prior to screening. 4. BMI \> 35 kg/m². 5. Patients treated with BiPAP or CPAP. 6. Known active tuberculosis. 7. A history of asthma, cystic fibrosis, central bronchiectasis, interstitial lung disease or pulmonary thromboembolic disease. 8. A history of thoracotomy with pulmonary resection. 9. Active or untreated malignancy.

Design outcomes

Primary

Measure	Time frame
To obtain patient specific geometries of the central and peripheral small airways	—
To obtain patient specific boundary conditions	—

Secondary

Measure	Time frame
To measure the resistance of the peripheral airways	—
To measure the reaction of the airways on various inhalation medications	—

Countries

Belgium

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026